Mesenchymal Stem Cells Derived from Umbilical Cord Blood Having Excellent Stemness Properties with Therapeutic Benefits - a New Era in Cancer Treatment.


Journal

Current stem cell research & therapy
ISSN: 2212-3946
Titre abrégé: Curr Stem Cell Res Ther
Pays: United Arab Emirates
ID NLM: 101272517

Informations de publication

Date de publication:
2022
Historique:
received: 25 12 2021
revised: 18 02 2022
accepted: 03 03 2022
pubmed: 27 4 2022
medline: 19 8 2022
entrez: 26 4 2022
Statut: ppublish

Résumé

Mesenchymal stem cells (MSCs) are the most promising candidates for cellular therapies, and most therapeutic applications have focused on MSCs produced from adult bone marrow, despite mounting evidence that MSCs are present in a wide range of conditions. Umbilical cord blood (UCB) is a valuable source of hematopoietic stem cells, but its therapeutic potential extends beyond the hematopoietic component, which also suggests solid organ regenerative potential. With potential ranging from embryonic- like to lineage-committed progenitor cells, many different stems and progenitor cell populations have been postulated. MSC is currently inferred by numerous clinical applications for human UCB. As stem cell therapy kicks off some new research and these cells show such a boon to stem cell therapy, it is nevertheless characteristic that the prospect of UCB conservation is gaining momentum. Taken together, the experience described here shows that MSCs derived from UCB are seen as attractive therapeutic candidates for various human disorders including cancer. It is argued that a therapeutic stem cell transplant, using stem cells from UCB, provides a reliable repository of early precursor cells that can be useful in a large number of different conditions, considering issues of safety, availability, transplant methodology, rejection, and side effects. In particular, we focus on the concept of isolation and expansion, comparing the phenotype with MSC derived from the UCB, describing the ability to differentiate, and lastly, the therapeutic potential concerning stromal support, stemness characteristic, immune modulation, and cancer stem cell therapy. Thus it is an overview of the therapeutic application of UCB derived MSCs, with a special emphasis on cancer. Besides, the current evidence on the double-edged sword of MSCs in cancer treatment and the latest advances in UCB-derived MSC in cancer research will be discussed.

Identifiants

pubmed: 35469574
pii: CSCR-EPUB-122841
doi: 10.2174/1574888X17666220425102154
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

328-338

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Suman Kumar Ray (SK)

Independent Researcher. Bhopal, Madhya Pradesh-462020, India.

Sukhes Mukherjee (S)

Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh-462020, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH